环胺和免疫抑制剂在系统性硬化症相关的间歇性肺部疾病中的有效性:元分析
Isha Anwar1, Darryl Sony2, Monika Chetry3
1House Surgeon, Department of General Medicine, Sri Siddhartha Medical College and Hospital, Tumakuru, Bengaluru, Karnataka, India, Orcid: https://orcid.org/0009-0009-5460-388X.
The Journal of the Association of Physicians of India
|September 16, 2025
概括
环胺 (CYC) 与安慰剂相比,对系统性硬化症相关的间歇性肺病 (SSc-ILD) 肺功能有好处. 然而,其他治疗方法,如阿扎西奥普林 (AZA),对于某些肺部参数可能更有效.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
背景情况:
- 系统性硬化症相关的间歇性肺病 (SSc-ILD) 是发病率和死亡率的主要原因.
- 免疫抑制疗法是管理SSc-ILD的基石,但最佳治疗仍在争论中.
- 环胺 (CYC) 已被研究,但其比较有效性需要进一步阐明.
研究的目的:
- 为了比较环胺 (CYC) 与安慰剂和其他免疫抑制剂在SSc-ILD中的疗效.
- 评估CYC对关键肺功能参数的影响.
- 进行网络元分析以进行全面的治疗比较.
主要方法:
- 随机试验和观察性研究的系统文献搜索.
- 包括比较CYC与安慰剂或其他免疫抑制剂的研究.
- 肺功能参数 (FVC,DLCO) 的元分析和网络元分析.
主要成果:
- 阿扎西奥普林 (AZA) 在强迫生命能力 (FVC) 和肺部对一氧化碳 (DLCO) 的扩散能力方面表现出优于CYC的优势.
- 在CYC和mycophenolate mofetil (MMF) 之间没有观察到FVC的显著差异.
- 与安慰剂相比,CYC改善了呼吸障碍指数得分,但没有显著改善DLCO.
结论:
- 目前的证据并不能确定CYC对大多数SSc-ILD肺功能参数的优越性.
- CYC和AZA显示了潜在的益处,但相对有效性有所不同.
- 进一步的严格研究对于优化SSc-ILD治疗策略和澄清CYC的作用至关重要.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
COPD: Management Using Bronchodilators and Corticosteroids
737
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
737
Drugs Used in Lower Respiratory Disorders: Overview
1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K
Cystic Fibrosis: Management
476
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
476


